At Emerald Bioscience, we are focused on advancing the medical benefits of cannabinoid-based therapies through our novel, proprietary, multi-cannabinoid drug platform for the treatment of significant unmet medical needs. This bioengineered platform, pioneered by the University of Mississippi, is considered an early mover in cannabinoid drug development. Modifying the molecules of the cannabis plant and creating synthetic cannabinoid derivatives, results in an optimized cannabinoid technology that enhances bioavailability and delivers more predictable pharmacokinetics.
Meet Our Team
Glaucoma. MRSA. Dry Eye Syndrome.
See the world's future through the potential of our proprietary cannabinoid-based therapies.
Our proprietary therapies continue to advance through preclinical and clinical development for various global medical indications.
Our platform is designed to enhance bioavailability and deliver more predictable pharmacokinetics.
Emerald Bioscience continues to establish relationships with industry leaders to further advance our research.
What are Cannabinoids?
March 25, 2019 | Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments
March 18, 2019 | Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
March 12, 2019 | Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues
Sign up for our Newsletter
Receive breaking news first!